Thu, Mar 5, 2015, 9:54 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • bnplapord Oct 22, 2013 9:03 AM Flag


    I think to make any sense out of this article, you would have to have more information. Basically, 148 started treatment with Arikace. 146 patients were treated with TOBI. At the end of the study there were 129 Arikace and 137 TOBI patients in the per protocol group, or 28 fewer patients than at the beginning. [19 Arikace and 9 TOBI patients missing.] I guess Feuerstein is saying Tobi is better because fewer patients dropped out. I would need more info such as why the 28 patients discontinued the treatment. Shorts are desperate after last weeks run up.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
20.33+1.33(+7.00%)Mar 5 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST